Autopsy report · NCT02245737

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease

“An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years before it stopped.
• 2,218 participants enrolled.
• Results were posted on the registry 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

AstraZeneca

Sponsor type

Industry

Conditions

Alzheimer´s Disease

Interventions

Lanabecestat; Placebo

Participants

2,218

Sites

254

Countries

Australia, Belgium, Canada, France, Germany, Hungary, Italy, Japan, Poland, Puerto Rico, Romania, South Korea and more

Trials that died the same way

• The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis
  “The trial was terminated early due to futility in reaching the primary endpoint.” (83% match in meaning)
• Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer
  “The trial was stopped for futility in view of the results of the anticipated analysis” (81% match in meaning)
• Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
  “Futility analysis did not support continuation of the trial” (77% match in meaning)
• Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)
  “Stage 1 interim analysis of efficacy met the criteria for early trial termination (futility). The trial was terminated at Stage 1; did not proceed to Stage 2.” (76% match in meaning)
• Removal Versus Retention of Cerclage in Preterm Premature Rupture of Membranes (PPROM)
  “This trial was terminated following a futility analysis confirming futility of continuing the study” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.